258 related articles for article (PubMed ID: 10446497)
1. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
Miyawaki S; Kobayashi T; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Omoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Ueda T; Tomonaga M; Ohno R
Int J Hematol; 1999 Jul; 70(1):56-7. PubMed ID: 10446497
[No Abstract] [Full Text] [Related]
2. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.
Löwenberg B
Blood; 2013 Jan; 121(1):26-8. PubMed ID: 23287624
[TBL] [Abstract][Full Text] [Related]
3. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
Magina KN; Pregartner G; Zebisch A; Wölfler A; Neumeister P; Greinix HT; Berghold A; Sill H
Blood; 2017 Aug; 130(7):946-948. PubMed ID: 28679736
[No Abstract] [Full Text] [Related]
4. Cytarabine-induced neurotoxicity responding to methyl prednisolone.
Malhotra P; Mahi S; Lal V; Kumari S; Jain S; Varma S
Am J Hematol; 2004 Dec; 77(4):416. PubMed ID: 15551283
[No Abstract] [Full Text] [Related]
5. [Petechiae, suffusions and cytarabine-induced erythema in treatment of acute myeloid leukemia].
Taverna C; Jacky E; Sauter C
Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1117. PubMed ID: 9691347
[No Abstract] [Full Text] [Related]
6. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
7. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
8. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
9. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Miyawaki S; Tanimoto M; Kobayashi T; Minami S; Tamura J; Omoto E; Kuriyama K; Hatake K; Saito K; Kanamaru A; Oh H; Ohtake S; Asou N; Sakamaki H; Yamada O; Jinnai I; Tsubaki K; Takeyama K; Hiraoka A; Matsuda S; Takahashi M; Shimazaki C; Adachi K; Kageyama S; Ohno R
Int J Hematol; 1999 Aug; 70(2):97-104. PubMed ID: 10497848
[TBL] [Abstract][Full Text] [Related]
10. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
11. Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?
Wiernik A; Sperr WR; Weisdorf D; Valent P; Ustun C
Am J Hematol; 2013 Jun; 88(6):533-4. PubMed ID: 23526441
[No Abstract] [Full Text] [Related]
12. Auto-SCT for AML in second remission: CALGB study 9620.
Linker CA; Owzar K; Powell B; Hurd D; Damon LE; Archer LE; Larson RA;
Bone Marrow Transplant; 2009 Sep; 44(6):353-9. PubMed ID: 19289999
[TBL] [Abstract][Full Text] [Related]
13. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
Sperr WR; Piribauer M; Wimazal F; Fonatsch C; Thalhammer-Scherrer R; Schwarzinger I; Geissler K; Knöbl P; Jäger U; Lechner K; Valent P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3965-71. PubMed ID: 15217926
[TBL] [Abstract][Full Text] [Related]
14. Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine.
Sitar DS; Aoki FY; Bow EJ
J Clin Pharmacol; 2008 Aug; 48(8):995-8. PubMed ID: 18495946
[No Abstract] [Full Text] [Related]
15. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study.
Shepshelovich D; Edel Y; Goldvaser H; Dujovny T; Wolach O; Raanani P
Br J Clin Pharmacol; 2015 Apr; 79(4):685-91. PubMed ID: 25303309
[TBL] [Abstract][Full Text] [Related]
16. Consolidation therapy: what should be the standard of care?
Rowe JM
Best Pract Res Clin Haematol; 2008 Mar; 21(1):53-60. PubMed ID: 18342812
[TBL] [Abstract][Full Text] [Related]
17. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
18. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
[TBL] [Abstract][Full Text] [Related]
19. Occurrence and therapy of secondary acute myeloid leukaemia in two HIV-infected patients.
Hengge UR; Schultewolter T; Uppenkamp T
AIDS; 1998 Jan; 12(2):221-2. PubMed ID: 9468375
[No Abstract] [Full Text] [Related]
20. High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine.
Johannsen KH; Handrup MM; Lausen B; Schrøder H; Hasle H
Pediatr Blood Cancer; 2013 Jul; 60(7):1154-60. PubMed ID: 23281248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
